Sökning: WFRF:(Thuresson Marcus) >
Lower cardiorenal r...
Lower cardiorenal risk withsodium-glucosecotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases : A large multinational observational study
-
- Birkeland, Kare I. (författare)
- Oslo Univ Hosp, Oslo, Norway.;Univ Oslo, Oslo, Norway.
-
- Bodegard, Johan (författare)
- AstraZeneca, Fredrik Selmersvei 6, N-0601 Oslo, Norway.
-
- Banerjee, Amitava (författare)
- UCL, Inst Hlth Informat, London, England.;Univ Coll London Hosp, Dept Cardiol, London, England.
-
visa fler...
-
- Kim, Dae Jung (författare)
- Ajou Univ, Sch Med, Dept Endocrinol & Metab, Suwon, South Korea.
-
- Norhammar, Anna (författare)
- Karolinska Institutet
-
- Eriksson, Jan (författare)
- Uppsala universitet,Klinisk diabetologi och metabolism
-
- Thuresson, Marcus (författare)
- Statisticon AB, Uppsala, Sweden.
-
- Okami, Suguru (författare)
- AstraZeneca, Osaka, Japan.
-
- Ha, Kyoung Hwa (författare)
- Ajou Univ, Sch Med, Dept Endocrinol & Metab, Suwon, South Korea.
-
- Kossack, Nils (författare)
- Wissensch Inst Gesundheitsokon & Gesundheitssyste, Leipzig, Germany.
-
- Mamza, Jil Billy (författare)
- AstraZeneca, Luton, Beds, England.
-
- Zhang, Ruiqi (författare)
- AstraZeneca, Luton, Beds, England.
-
- Yajima, Toshitaka (författare)
- AstraZeneca, Osaka, Japan.
-
- Komuro, Issei (författare)
- Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan.
-
- Kadowaki, Takashi (författare)
- Tranomon Hosp, Tokyo, Japan.
-
visa färre...
-
Oslo Univ Hosp, Oslo, Norway;Univ Oslo, Oslo, Norway. AstraZeneca, Fredrik Selmersvei 6, N-0601 Oslo, Norway. (creator_code:org_t)
- 2020-09-28
- 2021
- Engelska.
-
Ingår i: Diabetes, obesity and metabolism. - : John Wiley & Sons. - 1462-8902 .- 1463-1326. ; 23:1, s. 75-85
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://onlinelibrar...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aims We compared the new use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) versus dipeptidyl peptidase-4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart failure (HF) or chronic kidney disease (CKD), in patients with type 2 diabetes without a history of prevalent cardiovascular and renal disease, defined as cardiovascular and renal disease (CVRD) free, managed in routine clinical practice. Materials and methods In this observational cohort study, patients were identified from electronic health records from England, Germany, Japan, Norway, South Korea and Sweden, during 2012-2018. In total, 1 006 577 CVRD-free new users of SGLT2i or DPP4i were propensity score matched 1:1. Unadjusted Cox regression was used to estimate hazard ratios (HRs) for outcomes: cardiorenal disease, HF, CKD, stroke, myocardial infarction (MI), cardiovascular and all-cause mortality. Results Baseline characteristics were well balanced between the treatment groups (n = 105 130 in each group) with total follow-up of 187 955 patient years. Patients had a mean age of 56 years, 43% were women and they were indexed between 2013 and 2018. The most commonly used agents were dapagliflozin (91.7% of exposure time) and sitagliptin/linagliptin (55.0%), in the SGLT2i and DPP4i, groups, respectively. SGLT2i was associated with lower risk of cardiorenal disease, HF, CKD, all-cause and cardiovascular mortality; HR (95% confidence interval), 0.56 (0.42-0.74), 0.71 (0.59-0.86), 0.44 (0.28-0.69), 0.67 (0.59-0.77), and 0.61 (0.44-0.85), respectively. No differences were observed for stroke [0.87 (0.69-1.09)] and MI [0.94 (0.80-1.11)]. Conclusion In this multinational observational study, SGLT2i was associated with a lower risk of HF and CKD versus DPP4i in patients with type 2 diabetes otherwise free from both cardiovascular and renal disease.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- dapagliflozin
- diabetic nephropathy
- DPP-IV inhibitor
- heart failure
- observational study
- SGLT2 inhibitor
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Birkeland, Kare ...
-
Bodegard, Johan
-
Banerjee, Amitav ...
-
Kim, Dae Jung
-
Norhammar, Anna
-
Eriksson, Jan
-
visa fler...
-
Thuresson, Marcu ...
-
Okami, Suguru
-
Ha, Kyoung Hwa
-
Kossack, Nils
-
Mamza, Jil Billy
-
Zhang, Ruiqi
-
Yajima, Toshitak ...
-
Komuro, Issei
-
Kadowaki, Takash ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Diabetes, obesit ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet